Allyl isothiocyanate (AITC) is a naturally occurring compound that possesses both antimicrobial and anticancer activities. Many commonly consumed cruciferous vegetables are rich sources of AITC, such as mustard, horseradish, wasabi, and cabbage. Its bactericidal and fungicidal activities were demonstrated against a variety of pathogens, and its anticancer activities were shown in both cultured cancer cell lines and animal tumor models (1). Bioavailability of AITC is extremely high; nearly 90% of orally administered AITC is absorbed (1). Although available evidence indicates that the anticancer activity of AITC is neither cell- nor tissue-specific, we have recently shown that AITC is selectively delivered to bladder tissue through urinary excretion and potently inhibits cancer development and muscle invasion in an orthotopic rat bladder cancer model (2). Moreover, an AITC-rich mustard seed powder also strongly inhibited bladder cancer development and muscle invasion in vivo (3). Thus, AITC is highly promising for bladder cancer prevention and/or treatment. These results are also consistent with epidemiological studies showing an inverse association between consumption of cruciferous vegetables and bladder cancer risk (4, 5). In light of these findings, this study focuses on human bladder cancer cells.

Previous studies have shown that AITC causes cell cycle arrest and apoptosis in cancer cell lines of different tissue origins in vitro and in several tumor xenograft models in vivo, and it modulates many genes and proteins involved in cancer cell survival and proliferation (1). In our recent studies, both AITC and the AITC-rich mustard seed powder mentioned above arrested bladder cancer cells in G2/M phases and activated caspase-3 in bladder cancer cells in vitro and in bladder tumors in vivo (2, 3). However, it has not been determined whether AITC arrests cancer cells in both the G2 phase and M phase or only in one of the two phases. It is not known whether cell cycle arrest and apoptosis are linked to each other in AITC-treated cells. Answers to these questions are important for further development of this interesting agent against cancer. In this study, we show that AITC arrests bladder cancer cells exclusively in mitosis and targets two key proteins involved in mitosis. We also demonstrate that AITC induces mitochondrion-mediated apoptosis, but the apoptosis induction results entirely from mitotic arrest and that Bcl-2 phosphorylation by c-Jun N-terminal kinase (JNK) bridges mitotic arrest to apoptosis in response to AITC. Our study shows that AITC-treated cells die by mitotic catastrophe via Bcl-2 phosphorylation.

**EXPERIMENTAL PROCEDURES**

**Cells and Chemicals**—Three human bladder cancer cell lines, all derived from invasive transitional cell carcinomas, were used, including UM-UC-3 cells, UM-UC-6 cells, and T24 cells. Their sources and culture conditions have been described previously (6, 7). AITC, benzyl isothiocyanate (BITC), SP600125, and hydroxyurea (HU) were purchased from Sigma. Z-LEHD-FMK, rhodamine 123, MG-132, and JNK inhibitor XI (BI-87G3) were purchased from R & D Systems, Molecular Probes, EMD Millipore, and EMD/Calbiochem, respectively. HU was
dissolved in water; other agents were dissolved in acetonitrile or DMSO; solvent concentrations in culture medium was 0.1% (v/v). Antibodies specific for Bcl-2, p-Bcl-2 (Ser(P)-87), His tag (His-probe H3), cytochrome c (Cyt c), lamin B1, α-tubulin (for IP), β-tubulin (for IP), and γ-tubulin were purchased from Santa Cruz Biotechnology. Antibodies specific for Bad, Bak, Bax, Bcl-xl, Bid, p-Bcl-2 (Ser(P)-70), β-tubulin (for Western blotting), caspase-3, cleaved caspase-3, caspase-9, cleaved caspase-9, poly(ADP-ribose) polymerase (PARP), cleaved PARP, JNK, JNK1, JNK2, JNK3, p-JNK (Thr-183/Tyr-185), and voltage-dependent anion channel were purchased from Cell Signaling Technology. Antibodies specific for α-tubulin (for Western blotting), matrix metalloproteinase 9 (MMP-9), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from EMD/Calbiochem and Millipore, respectively.

Transient Gene Transfection—Cells were seeded in 10-cm dishes (1.5 × 10^6 cells/dish with 10 ml of medium) for 24 h and then transfected with pSFFV-neo (empty vector), pSFFV-HA-hBcl-2Δ (deletion of the loop domain of human Bcl-2 or amino acid residues 32–80), or pMT107–His-Ub (6× polyhistidine-tagged ubiquitin expression plasmid), 6–12 μg of DNA/dish and using FuGENE HD transfection reagent (Roche Applied Science); after 24 h, cells were treated with solvent or AITC for a desired time and then harvested for analysis.

Cell Cycle Analysis, Measurement of Mitochondrial Trans-membrane Potential, and TdT-mediated dUTP-biotin Nick End Labeling (TUNEL) Assay—Cells were seeded in 10-cm dishes (1.5–3 × 10^6 cells/dish with 10 ml of medium) for 24 h and then subjected to various treatments. At the end of each treatment, cells were processed for determination of cell cycle progression by flow cytometry as described previously (6). For measurement of mitochondrial trans-membrane potential, cells were first treated with vehicle or AITC and then trypsinized, washed, and centrifuged. Each cell pellet was resuspended in fresh medium at 5 × 10^5 cells/ml and then incubated with rhodamine 123 at 10 μg/ml for 30 min at 37 °C. The cells were then washed twice, resuspended in an equal volume of fresh medium, and measured by flow cytometry (1 × 10^6 cells/sample). For TUNEL assay, cells after treatment with AITC or solvent were processed using the MEBSTAIN® apoptosis kit (MBL International), following the manufacturer’s instruction, and finally measured for TUNEL-positive cells by flow cytometry.

Western Blot Analysis—Cells harvested after treatment with solvent or AITC were washed with ice-cold PBS and suspended in 1× cell lysis buffer (Cell Signaling), supplemented with 2 mM phenylmethylsulfonyl fluoride (PMSF) and a proteinase inhibitor mixture (Roche Applied Science). Cell lysis was enhanced by sonication. Mitochondria and cytosols were prepared based on a published protocol (8) with a minor modification. Briefly, ~2 × 10^7 cells were washed with ice-cold PBS, placed on ice for 10 min, and then suspended in 0.75 ml of an isotonic homogenization buffer (25 mM sucrose, 10 mM KCl, 1.5 mM MgCl_2, 1 mM NaEDTA, 1 mM NaEGTA, 1 mM dithiothreitol, 0.1 mM PMSF, 10 mM Tris-HCl, pH 7.4, and a proteinase inhibitor mixture from Roche Applied Science). The cells were stroked in a Dounce homogenizer. The homogenates were cleared by low speed centrifugation, and the supernatant was centrifuged at 12,000 × g for 20 min at 4 °C. The resultant supernatant was collected as cytosols, and the pellet containing mitochondria was washed three times with the homogenization buffer containing 0.01% Nonidet P-40 and then suspended in 1× cell lysis buffer (Cell Signaling). Protein contents were measured using a bichoninic acid assay kit (Pierce). The samples (20–40 μg each) were resolved by SDS-PAGE (8–12%, unless specified otherwise), which was followed by blotting to polyvinylidene fluoride membranes. The membranes were then probed by specific antibodies and the bands were visualized using the SuperSignal West Pico chemiluminescence kit (Thermo Scientific) or Amersham Biosciences ECL Plus kit (GE Healthcare).

Immunoprecipitation—Cells were lysed in 5 volumes of lysis buffer (10 mM Tris, pH 8.0, 0.25 mM EDTA, and 1% SDS), boiled immediately for 5 min, and then mixed with 10 volume of IP buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 0.1 mM EDTA, and 0.5% Tween 20). Isolated mitochondria were suspended in RIPA buffer (25 mM sucrose, 1 mM NaEGTA, 1 mM dithiothreitol, 0.1 mM PMSF, 10 mM Tris-HCl, pH 7.4, and a proteinase inhibitor mixture from Roche Applied Science). Cell lysates (0.5 mg of protein each) and mitochondrial samples (0.1 mg each) were incubated with a desired antibody (0.5–1 μg) overnight at 4 °C, followed by incubation with protein G-Sepharose beads for 1 h at room temperature or 4 °C. The beads were washed three times with IP buffer, suspended in 2× SDS loading buffer, boiled for 5 min, and used for Western blot analysis.

Mass Spectrometry—Purified porcine tubulins purchased from Cytoskeleton, Inc. (50 μg), were incubated with 30 μM AITC in 0.2 ml of PBS containing 1% acetonitrile in a glass vial for 1 h at 37 °C. A cold acetone precipitation was performed to remove unreacted AITC and salts. The protein precipitates were recovered by centrifugation, and the pellets were washed with cold 90% acetone and air-dried. The pellets were resuspended in 50 mM ammonium bicarbonate containing 10% acetonitrile, and the proteins were digested by trypsin (Sequencing Grade, Promega) at a ratio of 1:10 (w/w, trypsin/protein) at 37 °C for 2 h. The hydrolysis was stopped by the addition of formic acid to a final concentration of 2%. The samples were dried and reconstituted with 2% formic acid. The tryptic digests were analyzed by liquid chromatography, nanoelectrospray-tandem mass spectrometry (nanoLC-ESI-MS/MS) using a nanoACQUITY UPLC (Waters) coupled through a nebulization-assisted nanospray ionization source to a Q-ToF premier mass spectrometer (Waters/Micromass). MS/MS spectra were processed and transformed to the PKL file format using ProteinLynx Global Server version 2.3 (Waters/Micromass) and the default parameters of MaxEnt3 (Waters/Micromass). The PKL files were used to search a protein data base that was created using sequences obtained from GenBank™ and UniProt. Tubulin peptides modified by AITC at cysteine residues were identified by ProteinLynx Global Server and confirmed by manual inspection of the MS/MS fragment ion spectra (see supplemental material for further detail).

RT-PCR—Cells were treated with vehicle or AITC, from which total RNA was extracted using an RNasy Mini kit (Qiagen), and 1 μg of total RNA was reverse-transcribed using SuperScript® II reverse transcriptase (Invitrogen) in a 20-μl
reaction volume. PCRs were carried out in a total volume of 25 μl, containing 1 μl of cDNA template from the above-described reaction solution, 1× PCR buffer, 1.5 mM MgCl₂, 0.2 mM dNTPs, 10 pmol each of the forward and reverse primers, and 1 unit of TaqDNA polymerase (Invitrogen) under the following cycle conditions: denaturation at 94 °C for 2 min, 30 cycles of 94 °C for 30 s, 58 °C for 30 s, 72 °C for 30 s, and elongation at 72 °C for 5 min. The primers included those for α-tubulin (TUBA1, forward 5'-AGTTGATTATGGCAAGAATCC-3' and reverse 5'-CATCTGGTTGGCTGGCTC-3'), β-tubulin (TUBB, forward 5'-TGTGGTGCTGCTTACCTTG-3' and reverse 5'-CTACCCACTACCTTCTACCAT-3'), and GAPDH (forward 5'-CCAGGGCTGCTTTTAACTC-3' and reverse 5'-GCTCCCCCTGCAAATGA-3').

Wright-Giemsa Staining, Immunofluorescent Staining, and DNA Staining—For Wright-Giemsa staining, cells were seeded in 10-cm dishes (1.5 × 10⁶ cells/dish with 10 ml of medium) for 24 h and treated with solvent or AITC for 24 h. At the end of treatment, cells were harvested after trypsin treatment, washed with ice-cold PBS, and transferred to microscope slides using a Shandon Cytospin 4 from Thermo Electron Corp. Cells on the slides were dried at room temperature and stained with Wright-Giemsa solution (Sigma). After rinsing and air-drying, cover slides were affixed, and slides were analyzed by light microscopy. The percentage of mitotic figures was determined by analyzing a minimum of 150 cells in at least 20 fields per slide.

For immunofluorescent staining, cells were grown on 12-mm glass cover slides placed in 6 well plates (0.3 slide by analyzing a minimum of 150 cells in at least 20 fields per microscopy. The percentage of mitotic figures was determined by analyzing a minimum of 150 cells in at least 20 fields per slide.

For immunofluorescent staining, cells were grown on 12-mm glass cover slides placed in 6 well plates (0.3 × 10⁶ cells/slide with 2 ml of medium in each well) for 24 h and then exposed to solvent or AITC for 24 h. After washing once with ice-cold PBS, cells were fixed with 3.7% formaldehyde in PBS for 10 min at room temperature. Following three washes with PBS, the cells were permeabilized with wash buffer (0.1% Triton X-100 and 1% BSA in PBS) for 10 min and then treated with 10% mouse serum in PBS for 10 min. Following three more rinses with wash buffer, cells were incubated for 1 h at 37 °C with an antibody against α-tubulin. Following another three washes with wash buffer, cells were incubated with a fluorescein isothiocyanate (FITC)-conjugated secondary antibody (Santa Cruz Biotechnology) for 30 min in a dark chamber. Finally, cells were washed again with wash buffer and mounted on microscope slides with mounting medium (Molecular Probes), which contained 4',6-diamidino-2-phenylindole (DAPI) to counterstain DNA in cells. Fluorescence microscopy was used to analyze samples.

Tubulin Polymerization Assay—The effects of AITC and BITC (the latter was used as a control) on tubulin polymerization were assessed using a tubulin polymerization assay kit (BK0006) from Cytoskeleton, Inc., following the manufacturer’s instruction. Briefly, bovine brain tubulin (>99% purity) at the final concentration of 3 mg/ml was incubated with solvent or AITC or BITC at 37 °C. The reaction was carried out in prewarmed microtiter plates. Absorbance readings at 340 nm were taken immediately and once every minute for 20 min, using a SPECTRmax plate reader (Molecular Devices).

Statistical Analysis—Unpaired two-tailed Student’s t test was used for comparison between two groups. One-way analysis of variance was used for multigroup comparison, followed by Dunnett’s multiple comparison test.

RESULTS

AITC Causes G₂/M Arrest and Apoptosis in Human Bladder Cancer Cells—Multiple human bladder cancer cell lines were used to determine whether different cell line responds differently to AITC in terms of cell cycle arrest and apoptosis. Each cell line was treated with AITC at 0, 7.5, 15, and 30 μM for 24 h. The cells were checked either for cell cycle progression by flow cytometry or for apoptosis by a flow cytometry-based TUNEL assay. AITC caused dose-dependent and profound G₂/M arrest in all cell lines examined, with a corresponding decrease of the cell population in G₁ and S phases. Up to 90.1% of UM-UC-3 cells, up to 93.3% UM-UC-6 cells, and up to 74.5% of T24 cells existed in the G₂/M phase after AITC treatment, compared with 12.3–14.9% of control cells that were detected in these phases (Fig. 1A). At the same time, cells undergoing apoptosis also increased markedly after AITC treatment, as shown by an increase in both subG₁ population (see Figs. 2A and 3A for results of UM-UC-3 cells and results for UM-UC-6 cells and T24 cells not shown) and TUNEL-positive cells (Fig. 1B). Approximately 20% of the cells were TUNEL-positive after AITC treatment at the highest dose, compared with 2.1–7.1% in the control cells (Fig. 1B).

AITC Arrests Cells in Mitosis and Targets Both α- and β-Tubulin—To further understand AITC-induced cell cycle arrest, UM-UC-3 cells were treated with AITC at 15 μM for 24 h and then checked for both cell cycle arrest by flow cytometry
and mitotic figures (both mitotic cells and cells with multiple micronuclei) after Wright-Giemsa staining. 53.9% of AITC-treated cells were arrested in G2/M phase versus 13.1% in control cells (Fig. 2A), which were similar to that shown in Fig. 1A. Interestingly, Wright-Giemsa staining revealed that 56.5% of AITC-treated cells were in the mitotic phase versus 8.1% in control cells (Fig. 2B). Thus, AITC caused predominantly if not entirely mitotic arrest, rather than G2 phase arrest. It is also of note that a significant population of AITC-treated cells showed all features of a mitotic catastrophe (Fig. 2C), indicative of mitotic catastrophe. Simultaneous immunostaining of α-tubulin (Fig. 2C, green color) and DNA staining with DAPI (blue color) showed control cells undergoing typical mitosis and cell division (bipolar mitotic spindle and separation of sister chromosomes), whereas AITC-treated cells exhibited aberrant and multipolar mitotic spindle and lack of separation of sister chromosomes, reminiscent of the effects of vinblastine, which is a microtubule depolymerizer, and taxol, which is a microtubule stabilizer (9). However, AITC does not affect tubulin polymerization, as AITC at 50 and 100 μM had no effect on the rate of tubulin polymerization in an in vitro assay, whereas another isothiocyanate (BITC, used as a control) at the same concentrations had no effect on the rate of tubulin polymerization (Fig. 2D). Further experiments showed that AITC significantly down-regulated both α- and β-tubulin, but not γ-tubulin (Fig. 2E), suggesting that α- and β-tubulin may be key AITC targets for mitotic arrest. Interestingly, AITC had no effect on the transcripts of either α-tubulin gene or β-tubulin gene (Fig. 2F), indicating that AITC likely destabilized the proteins coded by these genes. Indeed, although treatment of UM-UC-3 cells with AITC (30 μM, 6 h) decreased the levels of both α- and β-tubulin (Fig. 3A), there was a marked increase in the levels of ubiquitinated α-tubulin and ubiquitinated β-tubulin (Fig. 3B), suggesting that AITC promoted the degradation of the tubulins via the ubiquitin (Ub)-proteasome pathway. Similar results were obtained in cells treated with AITC at 30 μM for 3 h (data not
shown). It is of note that the cells in the above experiments were transfected with a His-tagged Ub expression plasmid for 24 h before AITC treatment; in the absence of ectopic Ub expression, neither Ub-α-tubulin nor Ub-β-tubulin was detectable (data not shown). Moreover, incubation of purified porcine α-/β-tubulins with 30 μM AITC for 1 h at 37 °C resulted in binding of AITC to specific cysteine (Cys) residues, including Cys-127, Cys-347, and Cys-376 of α-tubulin, and Cys-12, Cys-239, Cys-303, and Cys-354 of β-tubulin, as shown by mass spectrometry analysis of trypsin-digested peptide fragments (Fig. 3C and supplemental Fig. S3). However, AITC binding to the cysteine residues was reversible, as the result described above was obtained after trypsin digestion of the AITC-treated tubulins for 2 h at 37 °C, whereas no cysteine modification by AITC could be detected after overnight incubation of the AITC-treated tubulins with trypsin (data not shown). The reversible nature of AITC binding to tubulin cysteines is consistent with our inability to detect AITC binding to cysteine residues of tubulins in UM-UC-3 cells, where the cells were treated with AITC at 30 μM for 3 h, from which α-/β-tubulins were isolated by immunoprecipitation and/or gel electrophoresis before they were subjected to trypsin digestion and mass spectrometry analysis. Nevertheless, the AITC-binding cysteine residues of the porcine tubulins, as described above, are also present in human α-/β-tubulins.

**AITC-induced Cell Death Depends on Mitotic Arrest and Is Associated with Phosphorylation of JNK and Bcl-2** —To further characterize mitotic arrest induced by AITC, UM-UC-3 cells were pretreated with or without 1 mM HU for 16 h and then treated with AITC at 15 and 30 μM for 24 h in the presence or
absence of HU. HU is a DNA replication inhibitor and arrests cells in G1 phase. Indeed, HU completely arrested UM-UC-3 cells in G1 phase and prevented AITC from arresting cells in mitosis, as measured by flow cytometry (Fig. 4, A and B). More interestingly, HU also prevented AITC from causing cell death, as subG1 population, which formed after AITC treatment (Fig. 4A), was no longer detected in cells co-treated with HU and AITC (Fig. 4B). Moreover, AITC stimulated Bcl-2 phosphorylation at Ser-70, although not at Ser-87 (antibodies specific for phosphorylation at each site were used), while not affecting total Bcl-2 expression (Figs. 4C and 7C). A subsequent experiment showed that AITC-induced Bcl-2 phosphorylation occurred exclusively in the mitochondria (Fig. 7C). However, HU completely blocked AITC-induced Bcl-2 phosphorylation (Fig. 4C), indicating that mitotic arrest is a prerequisite for AITC to induce Bcl-2 phosphorylation. Bcl-2 is a major anti-apoptotic protein, and Bcl-2 phosphorylation is well known to modulate its anti-apoptotic activity. Our finding that Bcl-2 phosphorylation was closely associated with the formation of subG1 cells after AITC treatment suggested that Bcl-2 phosphorylation might be key to AITC-induced cell death. Subsequent experiments showed that JNK was responsible for AITC-induced Bcl-2 phosphorylation. UM-UC-3 cells express both JNK1 (42 and 50 kDa) and JNK2 (54 kDa), but not JNK3, as detected by Western blotting using antibodies specific for each isoform (see supplemental Fig. S1). The results shown in Fig. 5A were obtained using antibodies detecting all JNKs or JNKs that are phosphorylated at Thr-183/Tyr-185, with no effect on the expression levels of total JNK1 and JNK2, as 3-h AITC treatment caused marked increase in p-JNK1/2; the effect was much attenuated after 24 h AITC treatment (Fig. 5A). Moreover, a specific JNK inhibitor (SP600125) inhibited AITC-induced Bcl-2 phosphorylation (Fig. 5B), and Bcl-2 Ser-70 is a known JNK phosphorylation site (10). Another JNK inhibitor XI, BI-87G3, which is structurally

FIGURE 5. JNK activation by AITC and its role in Bcl-2 phosphorylation. A, UM-UC-3 cells were pretreated with or without HU for 16 h and then treated with vehicle or AITC for 3 or 24 h in the presence or absence of HU, followed by Western blotting of JNK and p-JNK (Thr-183/Tyr-185). B, UM-UC-3 cells were pretreated with SP600125 (a JNK inhibitor) for 1 h and then co-treated with AITC and SP600125 for 24 h, followed by Western blotting of Bcl-2, p-Bcl-2 (Ser-70), and several other proteins. GAPDH is a loading control.

FIGURE 6. Effect of AITC on mitochondrion-mediated apoptosis. A, UM-UC-3 cells were treated with vehicle or AITC for 24 h, then labeled with rhodamine 123, and finally measured for loss of mitochondrial transmembrane potential (ΔΨm) by flow cytometry. Each value is mean ± S.D. (n = 3); *, p < 0.0001, compared with the control. B, UM-UC-3 cells were treated with vehicle or AITC for 24 h, from which cytosol and mitochondria were prepared and measured for Cyt c by Western blotting. Voltage-dependent anion channel (VDAC, a mitochondrial protein) was measured to rule out the presence of mitochondria in the cytosolic samples. MMP-9 (a cytosolic protein) was measured to rule out the presence of cytosolic materials in the mitochondrial samples. C, UM-UC-3 cells were pretreated with vehicle or a caspase 9 inhibitor (Z-LEHD-FMK, 20 μM) for 1 h and then exposed to AITC in the presence or absence of Z-LEHD-FMK (20 μM) for 24 h and then analyzed for the presence of apoptotic cells (TUNEL-positive cells) and for cell cycle arrest by flow cytometry. Each value is mean ± S.D. (n = 3).
Novel Anticancer Mechanism of Allyl Isothiocyanate

different from SP600125, also inhibited AITC-induced Bcl-2 phosphorylation in UM-UC-3 cells (supplemental Fig. S2). These results show that AITC causes Bcl-2 phosphorylation at Ser-70 via JNK activation. SP600125 also inhibited AITC-induced caspase 3 activation (Fig. 5B), providing further evidence that JNK-mediated Bcl-2 phosphorylation is important in AITC-induced cell death. However, JNK inhibition by SP600125 had no effect on down-regulation of α- and β-tubulins by AITC (Fig. 5B). Interestingly, in cells treated with both AITC and HU, there was a sustained JNK1/2 phosphorylation and a slight increase in JNK1 expression levels (Fig. 5A) but no Bcl-2 phosphorylation (Fig. 4B), hinting that AITC-activated JNK is not able to phosphorylate Bcl-2 unless cells are arrested in mitosis.

**AITC Acts ivates Mitochondrion-mediated Apoptosis**—Treatment of UM-UC-3 cells with AITC at 7.5–30 μM caused a dose-dependent and up to 6-fold loss of ΔΨm (mitochondrial transmembrane potential) (Fig. 6A), cytoplasmic accumulation of Cyt c and corresponding decrease of mitochondrial Cyt c (Fig. 6B), cleavage and/or activation of caspase-9, caspase-3, lamin B1, and PARP (Fig. 6C), and 7.2-fold increase in TUNEL-positive cells (Fig. 6D), clearly showing strong activation of the mitochondrial-mediated apoptosis by AITC. Both PARP and lamin B1 are known substrates of caspase-3. Moreover, a caspase-9 inhibitor (Z-LEHD-FMK, 20 μM) almost completely blocked AITC-induced cleavage of both caspase-3 and caspase-9 and the cleavage of PARP and lamin B1 (Fig. 6C), and it also prevented AITC from inducing TUNEL-positive cells (Fig. 6D), but it had no effect on AITC-induced cell cycle arrest (Fig. 6E). These results indicate that AITC caused the cells to die through mitochondrion-mediated apoptosis. The finding is consistent with the current understanding that cell death by mitotic catastrophe involves activation of the mitochondrial apoptotic pathway (11). It is also worth noting that, in the cytoplasmic fractions, we also observed marked decrease in both α- and β-tubulin levels after AITC treatment (result not shown).

**Bcl-2 Is Key to Apoptosis Activation by AITC**—As described above, Bcl-2 phosphorylation was closely associated with mitotic arrest and cell death after AITC treatment, and AITC-induced Bcl-2 phosphorylation occurred exclusively in the mitochondria (Fig. 7C); AITC strongly activated the mitochondrial apoptosis pathway, and a caspase-9 inhibitor completely blocked AITC-induced apoptosis (Fig. 6). In light of these findings, we asked if a Bcl-2 mutant lacking phosphorylation would inhibit AITC-induced cell death. We used a loop deletion Bcl-2 mutant with amino acid residues 32–80 removed. The loop domain of Bcl-2 contains Ser-70 and several other phosphorylation sites, and deletion of this domain was previously shown to block apoptosis induction by Taxol and other agents in certain cell lines (12, 13). UM-UC-3 cells were transfected with either the empty vector (pSFFV-neo) or the Bcl-2 mutant (pSFFV-HA-hBcl-2Δ), and 24 h after the transfection the cells were treated with either vehicle or AITC at 7.5–30 μM for 24 h. The Bcl-2 mutant was expressed ~3-fold higher than the endogenous Bcl-2 (Fig. 7A), and the expression levels of neither the endogenous Bcl-2 nor the mutant were influenced by AITC (Fig. 7A). The mutant did not affect AITC-induced phosphorylation of endogenous Bcl-2 (Fig. 7A). However, expression of the Bcl-2 mutant markedly attenuated the cleavage and/or activation of caspase-9, caspase-3, PARP, and lamin B1 (Fig. 7A). Moreover, induction of TUNEL-positive cells by AITC (30 μM, 24 h) was 73% lower in UM-UC-3 cells transfected with the Bcl-2 mutant than in cells transfected with the empty vector (Fig. 7B). It is possible that the inhibition of apoptosis might be even more complete, if the mutant could be expressed to higher levels.

We also examined the effect of AITC on several other Bcl-2 family members that are known to play a role in apoptosis, including Bak, Bcl-xl, Bad, Bax, and Bid. UM-UC-3 cells were treated with vehicle or AITC for 24 h, followed by Western
blotting of these proteins and Bcl-2. Except for Bak, which was detected only in the mitochondria, other proteins were detected in both the mitochondria and cytosol. However, AITC had no effect on their expression levels in either mitochondria or cytoplasm, except for stimulating Bcl-2 phosphorylation at Ser-70 in the mitochondria (Fig. 7C). Nevertheless, in UM-UC-3 cells treated with AITC for 24 h, Bcl-2 association with Bax in the mitochondria was disrupted, as measured by IP of purified mitochondrial lysates with anti-Bax and immunoblot with anti-Bcl-2 (Fig. 7D).

DISCUSSION

AITC causes G2/M arrest in a wide variety of human cancer cell lines, such as the three bladder cancer lines shown in this study, cervical cancer HeLa cells (14), colorectal cancer HT29 cells (15), and prostate cancer PC-3 cells and LNCaP cells (16). Using UM-UC-3 cell as a model and employing both flow cytometry and Wright-Giemsa staining, we have demonstrated that AITC arrests cancer cells in M phase, rather than G2 phase. Mitotic block was previously detected in AITC-treated HT29 cells by counting metaphase cells using transmission electron microscopy, but the study did not address the extent of mitotic arrest or whether AITC arrested HT29 cells in both G2 phase and M phase (15). Our results also indicate that AITC is a highly effective mitosis-blocking agent, as a single AITC treatment led up to more than 90% of the UM-UC-3 cells arrested. Unlike taxol and vinblastine, which are widely used in the clinic for cancer treatment and block mitosis by either stabilizing or destabilizing microtubule polymer, our study shows that AITC does not affect microtubule stability. Rather, AITC down-regulates both α- and β-tubulin, albeit not γ-tubulin. Thus, AITC is a new class of mitotic blocker. However, the ability of AITC to down-regulate α- and β-tubulin appears to be shared by other isothiocyanates, as Chung and co-workers (17, 18) recently showed that BITC, phenethyl isothiocyanate, and sulforaphane also down-regulated both tubulins in human lung cancer A549 cells and several other cell lines. These previous studies also showed that the isothiocyanates did not affect the transcription of the tubulin genes but stimulated proteasome-mediated degradation of the proteins. Indeed, this study showed that AITC had no effect on the transcript levels of both α- and β-tubulin but stimulated ubiquitination of both tubulins, indicating that AITC stimulates proteasome-mediated degradation of the tubulins. We further showed that AITC directly bound to multiple cysteine residues of both α-tubulin (Cys-127, Cys-347, and Cys-376) and β-tubulin (Cys-12, Cys-239, Cys-303, and Cys-354), but the binding was reversible. This is consistent with the knowledge that the \( N=C=S \) group of AITC is electrophilic and readily reacts with cysteine thiol, but the reaction is reversible (1). Although it remains to be determined if AITC binding to the cysteine residues or a specific cysteine residue of the tubulins is responsible for increased ubiquitination, most of the β-tubulin cysteine residues targeted by AITC have also been shown to be targeted by a number of antitumor agents, including Cys-12 by bis(4-fluorobenzyl)trisulfide and arsenic (19, 20), Cys-239 by 2-fluoro-1-methoxy-4-pentafluorophenyl-sulfonamidobenzene (21), and Cys-239 and Cys-354 by colchicine and colchicinoids (22, 23). Moreover, mutagenesis of Cys-12 or Cys-354 in β-tubulin was either lethal or significantly affected the structure and function of the tubulin in Saccharomyces cerevisiae (24).

Previous studies showed that cell cycle arrest in AITC-treated cells was always accompanied by apoptosis. This is also true for the three bladder cancer cell lines examined in this study; all of them showed cell cycle arrest, formation of subG1 cells, and TUNEL-positive cells in response to AITC. Using UM-UC-3 cells as a model, and preventing AITC from causing mitotic arrest by first arresting UM-UC-3 cells in G1 phase with HU, we found that AITC was no longer able to cause cell death. Moreover, although significant Bcl-2 phosphorylation was always associated with AITC-induced cell cycle arrest in all the bladder cancer cell lines examined in our study, such a change was no longer detected in cells pretreated with HU, followed by AITC. Thus, AITC-induced Bcl-2 phosphorylation depends on mitotic arrest. We further showed that AITC-induced Bcl-2 phosphorylation was associated with JNK activation (JNK1 and probably JNK2), and JNK inhibition prevented AITC from inducing Bcl-2 phosphorylation, indicating that AITC induces Bcl-2 phosphorylation by activating JNK. How AITC activates JNK remains unknown at this time. It is worth noting that both Taxol and vinblastine, both of which arrest cells in mitosis, also cause Bcl-2 phosphorylation (25, 26). Therefore, it seems likely that Bcl-2 phosphorylation occurs due to mitotic arrest, rather than an AITC-specific effect. Because Bcl-2 is a well known anti-apoptotic protein and Bcl-2 phosphorylation is known to affect its activity, we asked if Bcl-2 phosphorylation was involved in AITC-induced cell death. In UM-UC-3 cells, AITC-induced Bcl-2 phosphorylation occurred exclusively in the mitochondria. AITC did not modulate other Bcl-2 family proteins, including Bak, Bcl-xl, Bad, Bax, and Bid, but disrupted the association of Bcl-2 with Bax. AITC also activated the mitochondrion-mediated apoptosis, including the loss of mitochondrial transmembrane potential, cytoplasmic accumulation of Cyt c, activation of caspase-9, activation of caspase-3, and cleavage of PARP and lamin B1. Both PARP and lamin B1 are known substrates of caspase-3. This apoptotic pathway is essential for AITC to kill UM-UC-3 cells, as a caspase-9 inhibitor not only blocked AITC from activating both caspase-9 and caspase-3 and from causing cleavage of both lamin B1 and PARP but also blocked AITC from inducing the TUNEL-positive cells. Moreover, in cells transiently transfected with a Bcl-2 mutant that lacks the phosphorylation site, although the expression and AITC-induced phosphorylation of the endogenous Bcl-2 were not affected by the Bcl-2 mutant, AITC-induced apoptosis was markedly inhibited by the mutant, including inhibition of the activation of both caspase-9 and caspase-3, inhibition of the cleavage of both PARP and lamin B1, and inhibition of the formation of TUNEL-positive cells. Although the whole loop domain of Bcl-2 was deleted in this mutant, removing both the JNK phosphorylation site (Ser-70) and several other phosphorylation sites, it is of note that microtubule-targeting drugs typically induce Bcl-2 phosphorylation at Ser-70 and Ser-87 (27–29), but we showed that AITC did not stimulate Bcl-2 phosphorylation at Ser-87. Taken together, we conclude that Bcl-2 phosphorylation at Ser-70 bridges mitotic arrest to apoptosis in response to AITC.
In summary, our study shows that AITC binds to cysteine residues of α- and β-tubulin, promotes their ubiquitination and degradation, and arrests cancer cells exclusively in mitosis, which leads to cell death by mitotic catastrophe through the mitochondrion-mediated apoptosis. Bcl-2 phosphorylation at Ser-70, which is caused by JNK activation, is the molecular linker between mitotic arrest and apoptosis in AITC-treated cells. Moreover, AITC is a new class of mitosis blocker, as its mechanism of action differs from that of taxol and vinblastine that modulate tubulin polymer stability. Although these novel mechanisms of AITC in cancer cells of other tissue origins are warranted.

Acknowledgments—We greatly appreciate the gift of Bcl-2 mutant plasmid from Dr. Xinjiang Wang and the gift of pMT107-His-Ub plasmid from Dr. Craig B. Thompson (University of Pennsylvania).

REFERENCES

1. Zhang, Y. (2010) Mol. Nutr. Food Res. 54, 127–135
2. Bhattacharya, A., Tang, L., Li, Y., Geng, F., Paonessa, J. D., Chen, S. C., Wong, M. K., and Zhang, Y. (2010) Carcinogenesis 31, 281–286
3. Bhattacharya, A., Li, Y., Wade, K. L., Paonessa, J. D., Fahey, J. W., and Zhang, Y. (2010) Carcinogenesis 31, 2105–2110
4. Michaud, D. S., Spiegelman, D., Clinton, S. K., Rimm, E. B., Willett, W. C., and Giovannucci, E. L. (1999) J. Natl. Cancer Inst. 91, 605–613
5. Tang, L., Zirpoli, G. R., Guru, K., Moyalsh, K. B., Zhang, Y., Ambrosone, C. B., and McCann, S. E. (2008) Cancer Epidemiol. Biomarkers Prev. 17, 938–944
6. Tang, L., and Zhang, Y. (2004) J. Nutr. 134, 2004–2010
7. Tang, L., Li, G., Song, L., and Zhang, Y. (2006) Anticancer Drugs 17, 297–305
8. Yu, S. W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., and Dawson, V. L. (2002) Science 297, 259–263
9. Jo, H., Loison, F., Hattori, H., Silberstein, L. E., Yu, H., and Luo, H. R. (2010) PLoS One 5, e10318
10. Deng, X., Xiao, L., Lang, W., Gao, F., Ruvolo, P., and May, W. S., Jr. (2001) J. Biol. Chem. 276, 23681–23688
11. Castedo, M., Perfettini, J. L., Roumier, T., Andreau, K., Medema, R., and Kroemer, G. (2004) Oncogene 23, 2825–2837
12. Chang, B. S., Minn, A. I., Muchmore, S. W., Fesik, S. W., and Thompson, C. B. (1997) EMBO J. 16, 968–977
13. Srivastava, R. K., Mi, Q. S., Hardwick, J. M., and Longo, D. L. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 3775–3780
14. Hasegawa, T., Nishino, H., and Iwashima, A. (1993) Anticancer Drugs 4, 273–279
15. Smith, T. K., Lund, E. K., Parker, M. L., Clarke, R. G., and Johnson, I. T. (2004) Carcinogenesis 25, 1409–1415
16. Xiao, D., Srivastava, S. K., Lew, K. L., Zeng, Y., Hershberger, P., Johnson, C. S., Trump, D. L., and Singh, S. V. (2003) Carcinogenesis 24, 891–897
17. Mi, L., Xiao, Z., Hood, B. L., Dakshanamurthy, S., Wang, X., Govind, S., Conrads, T. P., Veenstra, T. D., and Chung, F. L. (2008) J. Biol. Chem. 283, 22136–22146
18. Mi, L., Gan, N., Cheema, A., Dakshanamurthy, S., Wang, X., Yang, D. C., and Chung, F. L. (2009) J. Biol. Chem. 284, 17039–17051
19. Xu, W., Xi, B., Wu, L., An, H., Zhu, J., Abassi, Y., Feinstein, S. C., Gaylord, M., Geng, B., Yan, H., Fan, W., Sui, M., Wang, X., and Xu, X. (2009) Mol. Cancer Ther. 8, 3318–3330
20. Zhang, X., Yang, F., Shim, J. Y., Kirk, K. L., Anderson, D. E., and Chen, X. (2007) Cancer Lett. 255, 95–106
21. Shan, B., Medina, J. C., Santha, E., Frankmoelle, W. P., Chou, T. C., Learned, R. M., Narbut, M. R., Stott, D., Wu, P., Jaen, J. C., Rosen, T., Timmermans, P. B., and Beckmann, H. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 5686–5691
22. Bai, R., Pei, X. F., Boyé, O., Getahun, Z., Grover, S., Bekisz, J., Nguyen, N. Y., Brossi, A., and Hamel, E. (1996) J. Biol. Chem. 271, 12639–12645
23. Bai, R., Covell, D. G., Pei, X. F., Ewell, J. B., Nguyen, N. Y., Brossi, A., and Hamel, E. (2000) J. Biol. Chem. 275, 40443–40452
24. Gupta, M. L., Jr., Bode, C. J., Dougherty, C. A., Marquez, R. T., and Himes, R. H. (2001) Cell Motil. Cytoskeleton 49, 67–77
25. Haldar, S., Chintapalli, J., and Croce, C. M. (1996) Cancer Res. 56, 1253–1255
26. Fan, M., Goodwin, M., Vu, T., Brantley-Finley, C., Gaarde, W. A., and Chambers, T. C. (2000) J. Biol. Chem. 275, 29980–29985
27. Yamamoto, K., Ichijo, H., and Kroemer, G. (2004) Oncogene 23, 8469–8478
28. Haldar, S., Basu, A., and Croce, C. M. (1998) Cancer Res. 58, 1609–1615
29. Basu, A., and Haldar, S. (1998) Int. J. Oncol. 13, 659–664